Pay in 4 interest-free payments of $5.30 Learn more
Ships within 48 hours · Estimated delivery Oct 27 - Nov 1
Novo Nordisks semaglutide, the GLP-1 analog used in Ozempic and Wegovy, showed an average weight loss of 10.6% at 68 weeks with the 2.4 mg dose in adults with type 2 diabetes and obesity or overweight in the STEP 2 Phase 3 trial
Microdosing can be appealing if you want to: Minimize nausea or gastrointestinal discomfort Ease into treatment without overwhelming your system Combine medication benefits with lifestyle changes for sustainable weight loss Stretch your prescription budget by using smaller doses over a longer period Who may consider microdosing
Molassiotis, A., Coventry, P
During treatment, patients can expect: Gradual dosing when appropriate Weekly self-administered injections Regular progress monitoring Support for side effects such as nausea or digestive changes Lifestyle guidance to support long-term success Ongoing communication with our team Everyone responds differently to medical weight-loss treatment
10.3 Are there any side effects associated with GLP-1s
US$ 23.80
US$ 27.23
US$ 29.17
US$ 24.04
